Citable filing context

VRTX filing events and research context

Server-rendered

VRTX's research view summarizes recent SEC filing context, starting with management_change from May 13, 2026.

VRTX filing events and research context
FiledItemContext
May 13, 2026management_changeShareholders elected 10 directors and approved the 2026 Stock and Option Plan at the Annual Meeting.
May 4, 2026earningsVertex reported Q1 2026 revenue of $2.99 billion, up 8%, and reiterated full-year 2026 financial guidance.
Apr 29, 2026management_changeDirector Suketu Upadhyay will not seek re-election due to new CFO role at Incyte Corporation.
May 4, 2026Guidance: gaap_rd_aiprd_sga_expenses6.30 to 6.45
May 4, 2026Guidance: non_cf_product_revenue0.50 to not reported
May 4, 2026Guidance: non_gaap_effective_tax_rate19.50 to 20.50
May 5, 2026mda_quarterlyVertex Pharmaceuticals reported an 8% increase in total revenues to $3.0 billion for Q1 2026, driven by continued strong performance of its cystic fibrosis (CF) therapies and diversification into new disease areas. ALYFTREK revenue surged by 687% to $424.4 million, benefiting from label extensions and new reimbursement agreements in international markets, while TRIKAFTA/KAFTRIO saw a 7% decline to $2.35 billion. Non-CF products, CASGEVY for sickle cell disease and beta thalassemia, generated $42.9 million, and JOURNAVX for acute pain contributed $29.0 million, both showing significant growth following recent launches and expanded market access, including Medicare Part D coverage for JOURNAVX. Operating expenses saw a 25% increase in selling, general, and administrative costs to $493.7 million, primarily due to commercialization investments for JOURNAVX and povetacicept. Research and development expenses remained stable at $961.6 million, reflecting ongoing investment in a diversified pipeline. The company is advancing povetacicept for IgA nephropathy with a BLA submission and Priority Review Voucher, progressing inaxaplin for APOL1-mediated kidney disease towards an early 2027 interim analysis, and resuming dosing for zimislecel in Type 1 diabetes. A notable risk is the ongoing arbitration with Royalty Pharma regarding the ALYFTREK royalty rate, where Royalty Pharma claims 8% versus Vertex's 4% position. Liquidity remains strong with $13.0 billion in cash and marketable securities, and $3.0 billion remains available under the share repurchase program.
Feb 13, 2026businessVertex Pharmaceuticals is a global biotechnology company developing transformative medicines for specialty markets. Its approved product portfolio includes a dominant position in Cystic Fibrosis (CF) with multiple CFTR modulators, such as ALYFTREK, which is expected to become the primary treatment for most CF patients. The company also markets CASGEVY, a CRISPR/Cas9 gene-editing therapy for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT), approved in major markets as a potential one-time functional cure. JOURNAVX, a non-opioid NaV1.8 inhibitor, was recently approved in the U.S. for acute pain. Vertex's robust pipeline emphasizes serial innovation and targets causal human biology. Key late-stage assets include povetacicept (dual BAFF/APRIL inhibitor) in Phase 3 for IgA Nephropathy (IgAN) with accelerated approval anticipated in H1 2026, and also in development for Primary Membranous Nephropathy (pMN) and Generalized Myasthenia Gravis (gMG). Inaxaplin, an APOL1 inhibitor, is in Phase 2/3 for APOL1-Mediated Kidney Disease (AMKD), with interim data expected late 2026/early 2027. Suzertrigine, a non-opioid NaV1.8 inhibitor, is in Phase 3 for Diabetic Peripheral Neuropathy (DPN). The Type 1 Diabetes (T1D) program, zimislecel (stem-cell therapy), is in Phase 1/2/3, though dosing is temporarily paused for manufacturing analysis. The company actively pursues strategic acquisitions and collaborations, such as with CRISPR for CASGEVY and Alpine for povetacicept, to expand its pipeline and leverage diverse modalities. Manufacturing complex cell and gene therapies, along with managing intellectual property, are ongoing operational focuses.

Source: SEC EDGAR filing text and events; period May 13, 2026; filed May 13, 2026.

Continue research

Keep researching VRTX

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →